

(19) World Intellectual Property
Organization
International Bureau



14 APR 2005



(43) International Publication Date
29 April 2004 (29.04.2004)

PCT

(10) International Publication Number
WO 2004/035062 A1

(51) International Patent Classification⁷: **A61K 31/7016**,
A61P 31/04

Farm, Queensland 4005 (AU). **GRATHWOHL, Matthias**
[DE/DE]; Haidelmoosweg 19, 78467 Konstanz (DE).
RAJARATNAM, Premraj [IN/AU]; 21 Malbon Street,
Eight Miles Plains, Queensland 4113 (AU).

(21) International Application Number:
PCT/AU2003/001377

(22) International Filing Date: 16 October 2003 (16.10.2003)

(74) Agent: **CULLEN & CO.**; Level 26, 239 George Street,
BRISBANE, Queensland 4000 (AU).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2002952121 17 October 2002 (17.10.2002) AU

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU,
SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (*for all designated States except US*): **AL-
CHEMIA PTY LTD** [AU/AU]; 3 Hi-Tech Court, Brisbane
Technology Park, Eight Miles Plains, Queensland 4113
(AU).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **MEUTERMANS**,
Wim [BE/AU]; 293 Birdwood Terrace, Toowong, Queens-
land 4066 (AU). **LE THANH, Giang** [AU/AU]; 38
Tarrant Street, MT GRAVATT, Queensland 4122 (AU).
ABBENANTE, Giovanni [AU/AU]; 53 Pringles Road,
Sampsonvale, Queensland 4520 (AU). **TOMETZKI**,
Gerald [GB/AU]; 106 Hardgreaves Road, Manly West,
Queensland 4179 (AU). **ADAMSON, George** [GB/GB];
2 Tudor Drive, Yately, Hampshire GU46 6BX (GB).
BECKER, Bernd [DE/AU]; 1/93 Langshaw Street, New

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: CARBOHYDRATE BASED ANTI-BACTERIALS



(57) Abstract: A method of inhibiting bacterial growth by contacting a bacteria with at least one disaccharide compound of General Formula (I).

WO 2004/035062 A1

CARBOHYDRATE BASED ANTI-BACTERIALS**FIELD OF THE INVENTION**

The invention relates to disaccharide compositions that have antibacterial properties.

5

BACKGROUND OF THE INVENTION

Bacteria have a great ability to generate resistance to drugs through lateral gene transfer, mutation of enzymes, or by expressing enzymes which actively pump out the drug or break it down. Over the past 10 years resistance to existing drugs has become a significant problem in many countries. No new antibacterial drugs have been developed over the past 15 years. Vancomycin is currently the drug of last resort to combat the multidrug resistant Gram-positive bacteria. In many places vancomycin-resistant *Staphylococcus aureus* and Enterococci (VRE) have been discovered. There is thus a desperate need for a new antibacterial drug to replace the drug of last resort.

15

There are a host of cytoplasmic targets for the development of new antibacterials, such as gyrase inhibitors, protein synthesis inhibitors, muramyl cascade inhibitors and many more. The major hurdle in designing such drugs is that in addition to enzyme based activity these drugs need to cross the bacterial cell wall to exert their antibacterial effect. On the other hand, enzymes involved in the stage III synthesis of the bacterial cell wall exist on the cell wall exterior, and therefore drugs inhibiting these enzymes can exert their bactericidal or bacteriostatic effect without having to cross the cell wall. Penicillin, cephalosporin and vancomycin are drugs that act on the transpeptidase enzymes which control the final steps in the peptidoglycan biosynthesis. Moenomycin is known to act on the transglycosylase enzymes, which are similarly involved in the polymerization of disaccharide precursors. Moenomycin displays very high potency at MIC level, and is used in animal feed as a growth promoter.

20

25

Moenomycin is a lipid-linked pentasaccharide. Through extensive SAR experiments it was realised that smaller fragments of moenomycin were capable of exerting antibacterial activity. Trisaccharide fragments of moenomycin still display antibacterial activity, but are not sufficiently stable to be useful drugs. On the basis of this, Sofia and coworkers discovered a new series of disaccharides, carrying aromatic

30

substituents in well defined positions around the disaccharide, which displayed significant MIC activity [WO0064915 and WO9926596].

A further class of disaccharide molecules, based on a sub-structure of vancomycin was shown to have antibacterial activity against vancomycin resistant bacteria. This class of molecules was subsequently demonstrated to contain transglycosylase inhibitors, and were not transpeptidase inhibitors as is vancomycin itself [WO9853813].


SUMMARY OF THE INVENTION

The present invention is directed to antibacterial compositions and is especially directed to a method of reducing bacterial growth by contacting bacteria with particular disaccharide like moieties.

The present invention may also be directed to an antibacterial pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one particular disaccharide like moiety.

The present invention may also be directed to a method of screening such compounds for anti-bacterial activity by contacting the compounds with a Gram-positive or Gram-negative bacteria and monitoring the growth or growth inhibition of the bacteria.

In a first aspect, the invention provides a method of inhibiting bacterial growth by contacting a bacteria with at least one disaccharide compound of General Formula I,




General Formula I

25


Wherein the pyranose rings may be of any configuration,

T is either R or -XR, where X is defined as oxygen, sulphur, NHC(O)-, and wherein R is selected from the non-limiting set comprised of H, or an alkyl, alkenyl, alkynyl,

- heteroalkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl of 1 to 20 atoms which is optionally substituted, and can be branched or linear. Typical substituents include but are not limited to OH, NO, NO₂, NH₂, N₃, halogen, CF₃, CHF₂, CH₂F, nitrile, alkoxy, aryloxy, amidine, guanidiniums, carboxylic acid, carboxylic acid ester, carboxylic acid amide, aryl, cycloalkyl, heteroalkyl, heteroaryl, aminoalkyl, aminodialkyl, aminotrialkyl, aminoacyl, carbonyl, substituted or unsubstituted imine, sulfate, sulfonamide, phosphate, phosphoramidate, hydrazide, hydroxamate, hydroxamic acid, heteroaryloxy, aminoalkyl, aminoaryl, aminoheteroaryl, thioalkyl, thioaryl or thioheteroaryl, which may optionally be further substituted,
- U and Z independently selected from OR, NHR, NR(R) (where R may be the same or different), or the following non-limiting set,




- R¹ and R² are independently selected from H, CH₃, CH₂XR, and C(O)NHR,
 R³ and R⁴ are independently selected from H, OH, OR, NHCOR, and
 W is independently selected from OR^L, NHR^L, NR^LR, or the following the following non-limiting set,



Wherein R^L is a substituted or unsubstituted, linear or branched, saturated or unsaturated C3 to C55 alkyl, heteroalkyl, arylalkyl, alkylaryl chain. Substituents may include but are not limited to acidic groups such as carboxylic acids, sulfonic acids, phosphoric acids, tetrazoles, or other carboxylic acid mimetics or basic groups such as amines, guanidines, amidines, imidazoles or other amine mimetics .

In a further aspect, the invention provides a method of inhibiting bacterial growth by contacting a bacteria with at least one disaccharide compound of General Formula II,




General Formula II

Wherein the disaccharide linkage is alpha or beta,
A is defined as hydrogen, OR or SR, and
 R , U , W , Z and R^4 are defined as in General Formula I.

In a more preferred aspect, the invention provides a method of inhibiting bacterial growth by contacting a bacteria with at least one disaccharide compound of General Formula III,

5



General Formula III

- 10 Wherein A is defined as in General Formula I, and
 U, Z, R^L and R⁴ are defined as in General Formula I.

The bacterial may be Gram-positive or Gram-negative bacteria. The bacteria may comprise an *E-coli* bacteria, a Staphylococci Bacteria such as
 15 *Staphylococcus aureus*, or other bacteria such as *Micrococcus luteus* (ATCC272),
 Staphylococcus aureus (ATCC29213), *Staphylococcus aureus* (ATCC43300) MRSA,
 Enterococcus faecalis (ATCC29212), *Enterococcus faecalis* (ATCC51299)
 Vancomycin resistant and *Streptococcus pyogenes* (ATCC8668).

20 The method may comprise administering an effective amount of a
 compound of the first aspect, to a subject in need of such treatment. The subject may
 be a human, or may be a domestic, companion or zoo animal.

In another form, the invention may reside in an antibacterial composition comprising at least one compound as described above. The composition may comprise a pharmaceutical composition.

25 The compounds of the invention may be mixed with a pharmaceutical acceptable carrier, adjuvant, or vehicle which may comprise a-toxic carrier, adjuvant, or vehicle that may be administered to a patient, together with a compound of this invention, and which does not destroy the pharmacological activity thereof.

The pharmaceutical derivative may comprise a salt, ester, salt of an ester or other derivative of a compound of this invention which, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention, although no limitation is meant thereby.

5 Compounds of the invention may be administered orally such as by means of a tableted, powder, liquid, emulsion, dispersion and the like; by inhalation; topically such as by means of a cream, ointment, salve etc; and as a suppository, although no limitation is meant thereby.


10 Methods and pharmaceutical carriers for preparation of pharmaceutical compositions are well known in the art, as set out in textbooks such as Remington's Pharmaceutical Sciences, 19th Edition, Mack Publishing Company, Easton, Pennsylvania, USA.

15 It will be clearly understood that, if a prior art publication is referred to herein, this reference does not constitute an admission that the publication forms part of the common general knowledge in the art in Australia or in any other country.

BEST MODE

MIC testing:

20 The broth microdilution format of the National Committee for Clinical Laboratory Standards (NCCLS) approved standard for susceptibility tests as outlined in M7-A4 "methods for dilution Antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard – fifth edition", January 2000 was utilized for minimum inhibitory concentration testing in Mueller-Hinton broth. The broth for *Streptococcus pyogenes* testing was supplemented with 2% laked horse blood. A positive result in initial testing was determined by complete inhibition of macroscopic
25 bacterial growth at a concentration of 128 micrograms per mL after incubation for 16 to 24 hours at 37 degrees C. In the case of *Micrococcus luteus*, incubation was at 30 degrees C.


Example 1

Comp. No.	R1	R2	Mass	R _f	SA24	SA48	EC24
1	A5	A9	679	4.62	+	n.d.	-


- 5 In all examples, + indicates an MIC value of less than 128 micrograms per mL, - indicates an MIC of greater than 128 micrograms per mL and n.d. indicates not determined.

Bacterial Types are:


- SA24 *S. aureus* after 24 hours exposure
 10 SA48 *S. aureus* after 48 hours exposure
 EC24 *E. coli* after 24 hours exposure

Example 2


Comp. No.	n	X	Y	R2	R3	MS	R _f	SA24	SA48	EC24
2	1	A1	A10	A11	A7	875	n.d.	+	+	-
3	1	A1	A10	A4	A9	831	n.d.	+	+	-
4	0	A1	A10	A12	A9	800	5.1	+	n.d.	-
5	0	A1	A10	A5	A7	862	4.92	+	+	-
6	0	A1	A10	A5	A9	851	5.36	+	n.d.	n.d.
7	1	A10	A1	A5	A7	876	5.01	+	+	-

Example 3

Comp. No.	R2	R3	MW	R _f	SA24	SA48	EC24
8	A5	A7	824	4.72	+	+	-
9	A5	A9	813	5.56	+	n.d.	n.d.


Example 4

Comp. No.	X	Y	R2	R3	MW	Rf	SA2 4	SA48	EC2 4
10	A1	A10	A12	A7	875	n.d.	+	+	-
11	A1	A10	A4	A9	831	5.18	+	+	+
12	A1	A10	A4	A7	843	4.65	+	+	+
13	A1	A10	A4	A1	663	3.2	+	n.d.	n.d.
14	A1	A10	A5	A9	864	5.27	+	+	-
15	A1	A10	A19	A9	863	4.85	+	+	+
16	A1	A10	A19	A7	875	4.23	+	+	+
19	A1	A10	A19	A25	849	4.8	+	+	+
20	A1	A10	A19	A22	861	3.49	+	+	+
21	A1	A10	A19	A16	889	3.57	+	+	+
22	A1	A10	A19	A23	930	5.1	+	+	+
23	A1	A10	A19	A26	831	3.56	+	+	+
24	A1	A10	A19	A27	899	4.22	+	+	+
25	A1	A10	A19	A28	904	3.3	+	+	+
26	A1	A10	A19	A29	918	3.5	+	+	+
27	A14	A1	A2	A9	800	5.01	+	n.d.	+
28	A14	A1	A3	A9	762	4.81	+	n.d.	+
29	A14	A1	A12	A9	764	4.92	+	n.d.	+
30	A14	A1	A4	A9	782	4.9	+	n.d.	+
31	A14	A1	A15	A9	765	5.4	+	n.d.	+

Example 5

Comp. No.	X	Y	R2	R3	MW	R _f	SA2 4	SA4 8	EC24
36	A10	A1	A17	A7	919	n.d.	+	+	n.d.
37	A10	A1	A5	A7	898	4.99	+	+	-
38	A1	A13	A2	A9	818	5.56	+	n.d.	n.d.
39	A1	A13	A5	A7	844	4.72	+	+	-
40	A1	A13	A5	A9	833	5.63	+	n.d.	-

5

Example 6


Comp.	R1	R2	R3	MW	R _f	SA24	SA48	EC24
42	A20	A20	A8	963	n.d.	+	n.d.	n.d.
43	A5	A1	A7	690	n.d.	+	n.d.	n.d.
44	A5	A3	A7	824	n.d.	+	+	n.d.
45	A5	A3	A1	644	3.82	+		n.d.
46	A5	A21	A7	822	4.73	n.d.	+	-
47	A5	A21	A1	642	3.39	+	n.d.	n.d.
48	A5	A17	A7	898	n.d.	+	+	-
49	A5	A4	A7	844	4.9	n.d.	+	-
50	A5	A4	A1	664	3.8	+	n.d.	n.d.

51	A5	A4	A9		n.d.	n.d.	n.d.	n.d.
52	A5	A44	A7	823	3.98	n.d.	+	-
55	A5	A5	A25	851	5.47	+	+	n.d.
56	A5	A5	C ₁₀ H ₂₁	837	5.38	+	+	n.d.
57	A5	A5	A39	857	4.9	+	+	n.d.
58	A5	A5	A40	861	5.01	+	+	n.d.
59	A5	A5	A22		n.d.	+	+	-
60	A5	A5	bis-pentyl	837	4.9	+	+	n.d.
61	A5	A5	A32	851	5.56	+	+	n.d.
62	A5	A5	A31	837	5.08	+	+	n.d.
63	A5	A5	A30	823	5.1	+	+	n.d.
64	A5	A5	A33	929	5.82	+	+	n.d.
65	A5	A5	A34	942	5.17	+	+	n.d.
66	A5	A5	A41	938	4.81	-	n.d.	n.d.
67	A5	A5	A42	952	4.89	-	n.d.	n.d.
68	A5	A5	A32	901	5.36	-	n.d.	n.d.
69	A5	A5	A36	901	5.45	+	n.d.	n.d.
70	A5	A5	A37	795	4.62	-	n.d.	n.d.
71	A5	A5	A46	880	4.62	-	n.d.	n.d.
72	A5	A5	A47	880	4.81	-	n.d.	n.d.
73	A5	A5	A6	893	5.1	+	n.d.	n.d.
74	A5	A5	A7	877	4.99	+	n.d.	n.d.
75	A5	A5	A23	932	5.63	+	n.d.	n.d.
76	A5	A5	A8	893	6.09	+	n.d.	n.d.
77	A5	A5	A9	865	5.63	+	+	-
78	A5	A3	A9	813	5.45	+	n.d.	n.d.
79	A5	A4	A9	833	5.73	+	n.d.	n.d.
80	A18	A4	A9	744	n.d.	+	n.d.	n.d.


The following compounds were tested against additional organisms with the following results.

1. *Micrococcus luteus* (ATCC272)
2. *Staphylococcus aureus* (ATCC29213)
- 5 3. *Staphylococcus aureus* (ATCC43300) MRSA
4. *Enterococcus faecalis* (ATCC29212)
5. *Enterococcus faecalis* (ATCC51299) Vancomycin resistant
6. *Streptococcus pyogenes* (ATCC8668)

Compound	1	2	3	4	5	6
76	+	+	+	+	+	+
42	+	+	+	+	+	+
75	+	+	+	+	+	+
68	+	+	-	+	-	+
65	+	-	-	+	-	+
69	+	+	+	+	-	+
70	+	-	-	+	-	+
73	+	+	+	+	+	+
74	+	+	+	+	+	+
66	-	-	-	-	-	+
67	+	+	+	+	+	+
77	+	+	+	+	+	+
51	+	+	+	+	+	+
56	+	+	+	+	+	+

TABLE 1 *Side Arms*

14




Throughout the specification and the claims unless the context requires otherwise, the term "comprise", or variations such as "comprises" or "comprising", will be understood to apply the inclusion of the stated integer or group of integers but not the exclusion of any other integer or group of integers.

- 5 It should be appreciated that various other changes and modifications can be made to any embodiment described without departing from the spirit and scope of the invention.

CLAIMS:

1. A method of inhibiting bacterial growth by contacting a bacteria with at least one disaccharide compound of General Formula I,



General Formula I

5


Wherein T is either R or -XR,

X is selected from the group consisting of oxygen, sulphur, NHC(O)-,

R is selected from the group consisting of: H, alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl of 1 to 20 carbon atoms,

10

U and Z are independently selected from the group consisting of: OR, NHR, NR(R) (wherein R may be the same or different), or




R¹ and R² are independently selected from the group consisting of: H, CH₃, CH₂XR, and C(O)NHR,

15

R³ and R⁴ are independently selected from the group consisting of H, OH, OR, NHCOR, and,

W is independently selected from the group consisting of OR^L, NHR^L, NR^LR, or



wherein R^L is selected from the group consisting of: a substituted or unsubstituted, linear or branched, saturated or unsaturated C3 to C55 alkyl, heteroalkyl, arylalkyl, alkylaryl chain.

5


2. The method of claim 1, wherein R^L is substituted by a moiety selected from the group consisting of: acidic groups, carboxylic acids, sulfonic acids, phosphoric acids, tetrazoles, or other carboxylic acid mimetics, basic groups, amines, guanidiniums, amidines, imidazoles, oxazoles, or other amine mimetics.

10

3. The method of claim 1, wherein one or more R groups is substituted by a moiety selected from the group consisting of: OH, NO, NO₂, NH₂, N₃, halogen, CF₃, CHF₂, CH₂F, nitrile, alkoxy, aryloxy, amidine, guanidiniums, carboxylic acid, carboxylic acid ester, carboxylic acid amide, aryl, cycloalkyl, heteroalkyl, heteroaryl, aminoalkyl, aminodialkyl, aminotrialkyl, aminoacyl, carbonyl, substituted or unsubstituted imine, sulfate, sulfonamide, phosphate, phosphoramidate, hydrazide, hydroxamate, hydroxamic acid, heteroaryloxy, carbamoyl, aminoaryl, aminoheteroaryl, thioalkyl, thioaryl or thioheteroaryl.

15


4. The method of claim 1, wherein the compound comprises



5 General Formula II

Wherein the disaccharide linkage is alpha or beta,
A is hydrogen, OR or SR.

5. The method of claim 1, wherein the compound comprises
- 10




General Formula III

Wherein A is hydrogen, OR or SR.

15

6. The method of claim 1, wherein the bacteria is a Gram + bacteria.
7. The method of claim 1, wherein the bacteria is a Gram – bacteria.
- 20 8. The method of claim 1, wherein the bacteria is selected from the group consisting of an *E-coli*, , *Micrococcus luteus*, *Staphylococcus aureus*, *Staphylococcus aureus* MRSA, *Enterococcus faecalis*, *Enterococcus faecalis* Vancomycin resistant and *Streptococcus pyogenes*.


9. The method of claim 1, wherein the bacteria is *Staphylococcus aureus* and the compound is



wherein R1 is A5 and R2 is A9

- 5 and wherein the substituents A are given in TABLE 1

10. The method of claim 1, wherein the bacteria is *Staphylococcus aureus* and the compound is



10


n	X	Y	R2	R3
1	A1	A10	A11	A7
1	A1	A10	A4	A9
0	A1	A10	A12	A9
0	A1	A10	A5	A7
0	A1	A10	A5	A9
1	A10	A1	A5	A7

and wherein the substituents A are given in TABLE 1

11. The method of claim 1, wherein the bacteria is *Staphylococcus aureus* and the compound is

15

20




R2	R3
A5	A7
A5	A9

and wherein the substituents A are given in TABLE 1

5

12. The method of claim 1, wherein the bacteria is *Staphylococcus aureus* and the compound is




10

X	Y	R2	R3
A1	A10	A12	A7
A1	A10	A4	A9
A1	A10	A4	A7
A1	A10	A4	A1
A1	A10	A5	A9
A1	A10	A19	A9
A1	A10	A19	A7

A1	A10	A19	A25
A1	A10	A19	A22
A1	A10	A19	A16
A1	A10	A19	A23
A1	A10	A19	A26
A1	A10	A19	A27
A1	A10	A19	A28
A1	A10	A19	A29
A14	A1	A2	A9
A14	A1	A3	A9
A14	A1	A12	A9
A14	A1	A4	A9
A14	A1	A15	A9

and wherein the substituents A are given in TABLE 1


13. The method of claim 1, wherein the bacteria is *Staphylococcus aureus* and the compound is



X	Y	R2	R3
A10	A1	A17	A7
A10	A1	A5	A7
A1	A13	A2	A9
A1	A13	A5	A7
A1	A13	A5	A9

and wherein the substituents A are given in TABLE 1

14. The method of claim 1, wherein the bacteria is *Staphylococcus aureus* and the compound is




5

R1	R2	R3
A20	A20	A8
A5	A1	A7
A5	A3	A7
A5	A3	A1
A5	A21	A7
A5	A21	A1
A5	A17	A7
A5	A4	A7
A5	A4	A1
A5	A44	A7
A5	A5	A25
A5	A5	C ₁₀ H ₂₁
A5	A5	A39
A5	A5	A40
A5	A5	A22
A5	A5	bis-pentyl
A5	A5	A32
A5	A5	A31
A5	A5	A30
A5	A5	A33
A5	A5	A34
A5	A5	A36
A5	A5	A6
A5	A5	A7
A5	A5	A23
A5	A5	A8
A5	A5	A9
A5	A3	A9
A5	A4	A9

A18	A4	A9
-----	----	----

and wherein the substituents A are given in TABLE 1

15. The method of claim 1, wherein the bacteria is *E. coli* and the compound is




5

X	Y	R2	R3
A1	A10	A4	A9
A1	A10	A4	A7
A1	A10	A19	A9
A1	A10	A19	A7
A1	A10	A19	A25
A1	A10	A19	A22
A1	A10	A19	A16
A1	A10	A19	A23
A1	A10	A19	A26
A1	A10	A19	A27
A1	A10	A19	A28
A1	A10	A19	A29
A14	A1	A2	A9
A14	A1	A3	A9
A14	A1	A12	A9
A14	A1	A4	A9
A14	A1	A15	A9

and wherein the substituents A are given in TABLE 1


16. The method of claim 1, wherein the compound is



Comp.	R1	R2	R3
42	A20	A20	A8
51	A5	A4	A9
56	A5	A5	C ₁₀ H ₂₁
65	A5	A5	A34
67	A5	A5	A42
68	A5	A5	A32
69	A5	A5	A36
70	A5	A5	A37
73	A5	A5	A6
74	A5	A5	A7
75	A5	A5	A23
76	A5	A5	A8
77	A5	A5	A9

- 5 and wherein the substituents A are given in TABLE 1
and the bacteria is *Micrococcus luteus*.

17. The method of claim 1, wherein the compound is



10


Comp.	R1	R2	R3
42	A20	A20	A8
51	A5	A4	A9

56	A5	A5	C ₁₀ H ₂₁
67	A5	A5	A42
68	A5	A5	A32
69	A5	A5	A36
73	A5	A5	A6
74	A5	A5	A7
75	A5	A5	A23
76	A5	A5	A8
77	A5	A5	A9

and wherein the substituents A are given in TABLE 1
and the bacteria is *Staphylococcus aureus*.

18. The method of claim 1, wherein the compound is

5




Comp.	R1	R2	R3
42	A20	A20	A8
51	A5	A4	A9
56	A5	A5	C ₁₀ H ₂₁
67	A5	A5	A42
69	A5	A5	A36
73	A5	A5	A6
74	A5	A5	A7
75	A5	A5	A23
76	A5	A5	A8
77	A5	A5	A9

and wherein the substituents A are given in TABLE 1
and wherein the bacteria is *Staphylococcus aureus* MRSA.

10


19. The method of claim 1, wherein the compound is



Comp.	R1	R2	R3
42	A20	A20	A8
51	A5	A4	A9
56	A5	A5	C ₁₀ H ₂₁
65	A5	A5	A34
67	A5	A5	A42
68	A5	A5	A32
69	A5	A5	A36
70	A5	A5	A37
73	A5	A5	A6
74	A5	A5	A7
75	A5	A5	A23
76	A5	A5	A8
77	A5	A5	A9

5 and wherein the substituents A are given in TABLE 1
and the bacteria is *Enterococcus faecalis*.

20. The method of claim 1, wherein the compound is



10

Comp.	R1	R2	R3
42	A20	A20	A8
51	A5	A4	A9
56	A5	A5	C ₁₀ H ₂₁
65	A5	A5	A34


67	A5	A5	A42
68	A5	A5	A32
69	A5	A5	A36
70	A5	A5	A37
73	A5	A5	A6
74	A5	A5	A7
75	A5	A5	A23
76	A5	A5	A8
77	A5	A5	A9

and wherein the substituents A are given in TABLE 1

and wherein the bacteria is *Enterococcus faecalis* Vancomycin resistant

21. The method of claim 1, wherein the compound is

5



Comp.	R1	R2	R3
42	A20	A20	A8
51	A5	A4	A9
56	A5	A5	C ₁₀ H ₂₁
65	A5	A5	A34
66	A5	A5	A41
67	A5	A5	A42
68	A5	A5	A32
69	A5	A5	A36
70	A5	A5	A37
73	A5	A5	A6
74	A5	A5	A7
75	A5	A5	A23
76	A5	A5	A8
77	A5	A5	A9

and wherein the substituents A are given in TABLE 1

and the bacteria is *Streptococcus pyogenes*

10

22. A method of inhibiting a bacterial infection in a mammal comprising administering an effective amount of a compound of claim 1 to the mammal.

23. An anti-bacterial pharmaceutical composition comprising a compound
5 of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

24. The method of claim 1, wherein the bacterium is a resistant or susceptible strain of a Micrococcus, Streptococcus, Enterococcus or Staphylococcus.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU03/01377

A. CLASSIFICATION OF SUBJECT MATTER												
Int. Cl. ⁷ : A61K 31/7016, A61P 31/04												
According to International Patent Classification (IPC) or to both national classification and IPC												
B. FIELDS SEARCHED												
Minimum documentation searched (classification system followed by classification symbols)												
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched												
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) DWPI; Keywords: micrococcus, streptococcus, enterococcus, staphylococcus, faecalis, pyogenes, aureus, luteus, coli and IPC A61K 031/7016, 031/70												
C. DOCUMENTS CONSIDERED TO BE RELEVANT												
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.										
A	WO 99/26956 A1 (INTERCARDIA INC) 3 June 1999 See the abstract and the claims	1-24										
A	WO 98/53813 A1 (INTERCARDIA INC) 3 December 1998 See the claims	1-24										
A	WO 00/64915 A1 (IRL INC) 2 November 2000 See page 3 last paragraph to page 5 third paragraph	1-24										
<input type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex												
<p>* Special categories of cited documents:</p> <table border="0"> <tr> <td>"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"E" earlier application or patent but published on or after the international filing date</td> <td>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td>"&" document member of the same patent family</td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family	"P" document published prior to the international filing date but later than the priority date claimed	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention											
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone											
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art											
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family											
"P" document published prior to the international filing date but later than the priority date claimed												
Date of the actual completion of the international search 4 December 2003		Date of mailing of the international search report 16 DEC 2003 16 DEC 2003										
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaaustralia.gov.au Facsimile No. (02) 6285 3929		Authorized officer S. Chew Telephone No : (02) 6283 2248										

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/AU03/01377

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member			
WO	99/26956	AU	15879/99	EP	1047703	JP	2001524484
		US	6114309	US	6207820	WO	6274716
WO	98/53813	AU	77000/98	EP	0998280	JP	2002502393
WO	00/64915	AU	46651/00				END OF ANNEX